Dr. Leonid Gibiansky is the founder and president of QuantPharm LLC.
Dr. Gibiansky obtained his Ph.D. degree in Applied Mathematics and Mathematical Physics from Ioffe Physical Institute (Russian Academy of Science) in 1988. In 1991 he was invited to Courant Institute of Mathematical Sciences (New York University). He worked at New York University and then at Princeton University developing theory of optimal design in application to mathematical physics. In 1999, Leonid started to work in the area of drug development focusing on application of advanced mathematical and statistical methods to model-based drug development. Overall, he has more than 30 years of academic and industry experience in areas as diverse as pharmacometrics, PK-PD modeling and simulation, in vitro-in vivo correlations, statistical design and analysis of clinical trials, statistical algorithm design and software development, bioinformatics, and optimization in mathematical physics. In 2007, Leonid founded QuantPharm LLC that provides modeling and simulation and drug development consulting services to pharmaceutical and biotechnology industries. He is the author of more than 100 original research papers and scientific abstracts. He holds several US and international patents.
Dr. Ekaterina Gibiansky is CEO & CSO of QuantPharm LLC.
Dr. Gibiansky obtained her Ph.D. degree in Statistics from University of Greenwich, London, UK. She started her pharmaceutical industry career in 1992 in the first-in-industry modeling and simulation group in the Clinical Pharmacology department of Novartis Pharmaceuticals. Subsequently, she worked in small and large pharmaceutical companies, biotech companies, and consulting companies, progressively moving from the statistician-pharmacometrician position in Novartis to the Senior Director, PKPD, Modeling & Simulation in Icon Development Solutions. In 2009, Ekaterina joined QuantPharm LLC in the role of CEO and CSO. She has a broad drug development and modeling expertise and an extensive experience in interactions with clinical teams, advisory boards, and the FDA. She published more than 50 original research papers and scientific abstracts and holds several US and international patents.